Mersana Therapeutics, Inc.

NasdaqGS:MRSN 주식 보고서

시가총액: US$244.6m

Mersana Therapeutics 관리

관리 기준 확인 2/4

Mersana Therapeutics CEO는 Marty Huber, Sep2023 에 임명되었습니다 의 임기는 1.17 년입니다. 총 연간 보상은 $ 3.04M, 6.4% 로 구성됩니다. 6.4% 급여 및 93.6% 보너스(회사 주식 및 옵션 포함). 는 $ 230.34K 가치에 해당하는 회사 주식의 0.094% 직접 소유합니다. 230.34K. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 7.5 년입니다.

주요 정보

Marty Huber

최고 경영자

US$3.0m

총 보상

CEO 급여 비율6.4%
CEO 임기1.2yrs
CEO 소유권0.09%
경영진 평균 재임 기간4.3yrs
이사회 평균 재임 기간7.5yrs

최근 관리 업데이트

Recent updates

Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly?

Nov 08
Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth

Oct 03
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth

Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade

Aug 15
Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade

Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%

Aug 13
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues

Jun 19
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues

Mersana Therapeutics: On Hold While Waiting For Any Positive News

May 15

Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%

Apr 25
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry

Feb 27
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry

Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock

Jan 11

Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Oct 14
Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Jun 09
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Feb 22
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Mersana gains as FDA grants fast track status for breast cancer drug

Sep 12

Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed

Aug 15

Taking The Measure Of Mersana Therapeutics

Jan 10

Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress

Jun 29

It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Jun 05
It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Mersana Therapeutics EPS misses by $0.11, misses on revenue

May 10

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Mar 23
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

Jan 29
Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

CEO 보상 분석

Marty Huber 의 보수는 Mersana Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$75m

Jun 30 2024n/an/a

-US$105m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$3mUS$194k

-US$172m

Sep 30 2023n/an/a

-US$197m

Jun 30 2023n/an/a

-US$215m

Mar 31 2023n/an/a

-US$213m

Dec 31 2022US$163kn/a

-US$204m

Sep 30 2022n/an/a

-US$208m

Jun 30 2022n/an/a

-US$194m

Mar 31 2022n/an/a

-US$183m

Dec 31 2021US$290kn/a

-US$170m

Sep 30 2021n/an/a

-US$150m

Jun 30 2021n/an/a

-US$127m

Mar 31 2021n/an/a

-US$106m

Dec 31 2020US$303kn/a

-US$88m

보상 대 시장: Marty 의 총 보상 ($USD 3.04M )은 US 시장( $USD 1.47M ).

보상과 수익: 회사가 수익성이 없는 동안 Marty 의 보상이 증가했습니다.

CEO

Marty Huber (63 yo)

1.2yrs

테뉴어

US$3,044,085

보상

Dr. Martin H. Huber, also known as Marty, M.D., is President and Chief Executive Officer at Mersana Therapeutics, Inc. since September 2023. He served as President and Head of R&D at Xilio Therapeutics, In...

리더십 팀

이름위치테뉴어보상소유권
Martin Huber
President1.2yrsUS$3.04m0.094%
$ 230.3k
Brian DeSchuytner
Senior VP5.3yrsUS$1.74m0.077%
$ 187.8k
Timothy Lowinger
Senior VP and Chief Science & Technology Officer16.8yrsUS$1.69m0.19%
$ 466.6k
Alejandra Carvajal
Senior VP3.6yrsUS$1.61m0.052%
$ 126.2k
Mohan Bala
Senior VP & Chief Development Officer3.1yrsUS$1.58m0.044%
$ 108.4k
Mikhail Papisov
Co-Founderno data데이터 없음데이터 없음
Ashish Mandelia
Chief Accounting Officer5.2yrs데이터 없음0.039%
$ 94.6k
Jason Fredette
Senior Vice President of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Chuck Miller
Senior Vice President of Regulatory Affairs4.3yrs데이터 없음데이터 없음
Marc Damelin
Exe. Director and Head of Biologyno data데이터 없음데이터 없음

4.3yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: MRSN 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Martin Huber
President4.6yrsUS$3.04m0.094%
$ 230.3k
David Mott
Independent Chairman12.3yrsUS$329.93k0.47%
$ 1.2m
Peter Kiener
Member of the Scientific Advisory Boardno data데이터 없음데이터 없음
Lawrence Alleva
Independent Director7.2yrsUS$308.93k0.0017%
$ 4.2k
Willard Dere
Independent Director6.7yrsUS$305.43k0.020%
$ 48.9k
Kristen Hege
Independent Director8.3yrsUS$293.43k0%
$ 0
Anna Protopapas
Director9.7yrsUS$4.65m0.34%
$ 833.6k
Andrew A. Hack
Independent Director7.8yrsUS$297.43k0%
$ 0
Misti Ushio
Board Observerno data데이터 없음데이터 없음
Howard Burris
Member of the Scientific Advisory Boardno data데이터 없음데이터 없음
Allene Diaz
Independent Director3.7yrsUS$294.93k0%
$ 0
K. Wittrup
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

7.5yrs

평균 재임 기간

60.5yo

평균 연령

경험이 풍부한 이사회: MRSN 의 이사회는 경험(평균 재직 기간 7.5 년)으로 간주됩니다.